In past years, I and ten family members have struggled to heal from severe #LymeDisease. Some of us were bedridden for prolonged periods, sometimes missing out on Thanksgiving and Christmas gatherings.

The “behind the scenes” impulse to develop new treatments, such as INPT, was to heal real illness in my own family, as well as those people under my care at the Biologix Center for Optimum Health.

As we near the holiday season, this new innovation has given us much to be thankful for…God’s inspiration to develop INPT, and the development of the Borrelia-phage test by scientists at Leicester University, and that we can all gather around the table together this year.

Healing from Lyme Disease

While the elimination of all of the Borrelia bacteria and co-infections in a person with Lyme disease is extremely important, it is just as important to address the damage to the tissues and systems of the body. The following will reveal how a new discovery has lead to what appears to be the incredibly rapid and complete elimination of the infection. The damage is now what takes time and skill to eliminate, so that optimum health can be restored. The often dramatic improvements in patients symptoms have been achieved by combining the new innovation, INPT, in combination with a 1-2 week program of daily treatments and therapies.

Induced Native Phage Therapy (INPT), is a new, patent-pending oral therapeutic, thought to activate epigenetic changes in naturally occurring, “native” phages, that already reside within the patient. These epigenetic changes appear to cause the native phages to revert from lysogenic activities to lytic swarming to rapidly eliminate the targeted microbes within the patient. The INPT remedy is administered orally and is designed to induce native bacteriophages (phages) to switch from their normal lysogenic activities in relation to their specific host bacteria, turning instead to lytic actions, appears to be able to eliminate all Borrelia spp. and it’s Persister Cells located anywhere in the body.

Of the 12 people in the study who originally tested positive for one or more strains of Borrelia, with one week of INPT treatment, all twelve were retested and found to be negative for any residual Borrelia infection. A confirmatory third test was performed around 70 days post INPT treatment which determined all participants remained negative. The long-term elimination of the detection of Borrelia, using the most sensitive test developed to date, is a strong proof of concept and verification of the science of Induced Native Phage Therapy (INPT).

Understanding Phages

Each type of phage uses a very specific type of bacteria in a parasitic relationship, forcing their bacterial host to incorporate the phage genetics into the host genetic engine, thereby causing the host to replicate more of the phages. INPT is a new technology that enables the inducing of any specific phage-type to target and rapidly kill their specific microbial host, through lytic action. INPT is based upon leading research demonstrating every human infection enters the body already infected with its own phage infection specific to that infectious bacterial type. This phage infection of the bacteria is a parasitic relationship, which INPT can cause the phages to become predatory, seeking out and killing all of their specific host bacteria. The activated phages themselves die within three days after the last of their target bacteria are dead.

With INPT, no externally-sourced phages are being introduced into the body, as is the case in the rest of the body of phage science. INPT works with bacteriophages that already exist within the body, that enter the body in situ, within the initial infecting microbe from the various vectors, such as ticks.

Recent research reported by Tatjana Mijatovic, PhD, at the 2020 ILADS (International Lyme and Associated Diseases) conference, confirms Borrelia inside of a tick’s stomach are themselves already parasitically infected by Borrelia-phages. These Borrelia-phages enter the human body with the injection of the bacteria during the tick bite.

Range of Effectiveness of INPT

Research has verified that phages can naturally go from the normal parasitic relationship with their host bacteria called, lysogenic activity, to suddenly switching to swarming, killing all of their host bacteria through lytic activity. This dramatic change can be triggered by subtle changes in their environment, the body. INPT was developed to strategically induce or stimulate this natural swarming activity of phages.

INPT has been utilized to help the body address dozens of types of microbes in over 300 chronically ill people, with never before seen results. At this time, there is only one type of laboratory test available to document this work, the Phelix Borrelia-Phage test, the most sensitive Borrelia spp. test to date. Of these 300 people, 30 of these people with previously diagnosed, non-responsive Borrelia spirochete infections have undergone three rounds of Phelix Borrelia-Phage testing.

All patients had previous laboratory diagnosis and extensive, yet unsuccessful conventional and natural anti-Borrelia treatments. Prior to treatment with INPT, an initial Phelix Borrelia-Phage test was used to document that they did indeed have the Borrelia still. Each were found to be positive.

INPT was administer for 5 days after which it was discontinued. Seven days later, a time deemed necessary to allow the Borrelia-phages to die-off, having no Borrelia host to continue replicating more Borrelia-phage, a second Phelix test was performed to confirm the Borrelia has been completely eliminated. These second tests showed that 100% of the people were negative for any residual Borrelia after just 5 days of actual INPT treatment.

If all of the Borrelia bacteria are truly eliminated, the phages themselves die due to the fact that there are no more of the host bacteria left to replicate more of the phages.

The phages will only live three to four days beyond the death of their host bacteria, the Borrelia. Therefore, a total of seven days after the last day of INPT treatment were allowed in order to ensure the last of the Borrelia-phages were also dead, since the Phelix Borrelia-Phage test, is looking for the Borrelia-phages. If there are Borrelia bacteria still in the body after the INPT treatment, there will be Borrelia-phages still remaining in the body, and these phages will be easily detected via the testing.

Long-term Elimination of Borrelia

Of the people who initially tested positive and were found to be negative on their second test, a third confirmatory Phelix test was performed 45-60 days after the second test. All of the third tests remained negative, confirming long-term elimination.

Clinical improvements were often above expectations, while others who had suffered from years of damage to their tissues as a result of the many failed treatments and the illness itself, experienced slight improvement or remained symptomatic. These symptom improvements are another confirmation and proof of concept.

Of the 280 people, there were none to mild worsening (Jarisch-Herxheimer reactions) of symptoms reported, in spite of the speed of Borrelia elimination, due to the way phages kill the bacteria, which is unlike the mechanism of action of antibiotics. The reason for the rapid elimination and minimal “herx” reactions is explained in this article. INPT appears to able to target Borrelia and eliminate it within two weeks, without toxic and potentially harmful effects, which are common with all antibiotics, as documented by the newest and most sensitive Borrelia testing, the Phelix Borrelia-Phage Test.

Discussion

Treatment-resistant, chronic and apparent relapsing Lyme disease (borreliosis), with its oft associated co-infections which worsen the illness, though once debated, is now well-documented in the scientific literature. Chronic Lyme disease has reached the true status of a global pandemic, though largely unappreciated by the media and mainstream medicine. The politics of medical policy bias prevails in many if not most mainstream medical schools and associations. Due to the prevalence of medical bias against the recognition of the common occurrence of chronic and persistent nature of Lyme disease, the development of out-of-the-box thinking in the treatment has been limited to trial and error, often resulting in increased improvements, as well as increased suffering caused by varied and long-term antibiotics by more forward thinking physicians. The desperation of those suffering from Lyme Disease leads many to rush to the next newest antibiotic in a Russian-Roulette of risking being one of the many people whose symptoms worsen instead of improve with the latest antibiotic, such as Disulfiram, which helps some people, yet harms others.

As stated by Kenneth Liegner, MD in his journal article on the use of Disulfiram for the treatment of Lyme Disease, reporting on the successful treatment of three patients using Disulfiram, “The persistence of borrelial and piroplasm infections despite treatment poses a dilemma for patients and physicians alike. Failure to treat may subject the patient to personal suffering, deterioration, and loss of function, and can eventuate in death [3,4,5,13,15,59,60,61,62,63,64,65,66] (Supplementary File 1, 2a and 2b). Open-ended antimicrobial treatment is costly, requires medical oversight for safety, entails risks—including the risk of death—and theoretically risks the emergence of resistant strains of microbes, with public health implications [67,68].

In another peer-reviewed article, by Alain Trautmann, et. al., titled, Potential Patient-Reported Toxicities With Disulfiram Treatment in Late Disseminated Lyme Disease, it is reported that there are, “…severe and persistent toxic events in a patients suffering from a late disseminated form of Lyme Disease following disulfiram intake.” The article goes on to conclude that, “Thirteen out of 16 patients reported toxic events, and seven out of 16 reported benefits for at least part of their symptoms. Based on the collected observations, it seems too early to promote disulfiram as a promising new treatment until the reasons underlying the reported toxicities have been explored, and the results of a well-conducted double blind clinical trial published.

The need for a truly effective and non-toxic treatment must be developed, and as you will read, has been developed.

INPT Yields Encouraging Results

Induced Native Phage Therapy (INPT), has shown exciting clinical results as well as establishing laboratory verification of its effectiveness, as no other explanation can be found to explain the highly statistically-improbable finding of repeat negative Phelix tests after INPT.

Bacteriophages, or phages, are well researched, yet INPT is a completely new application of the science and appears to work by stimulating specific phages to swarm the target bacteria and completely eliminate even the difficult to reach bacteria that are coated with biofilms, and the pleomorphic forms called L-Forms and other forms called, “persistor cells.” INPT is not to be compared to or thought of as any other previous use of bacteriophages, due to the fact that no bacteriophages are being introduced into the body from outside sources, but instead INPT is thought to stimulate the regulative epigenetic switches of native bacteriophages already living in the body.

These never before seen results, appear to support the science behind INPT as a viable solution of complete elimination of the Borrelia, with minimal to no adverse side-effects or Herxheimer reactions, and no risk of creating treatment-resistant strains of bacteria.

Results after One Week of INPT Treatment

Of the people initially tested with the Phelix Borrelia-Phage test, twelve people tested as positive, confirming each patient did indeed still have Borrelia sp. infection, in spite of previous prolonged pharmaceutical and natural antimicrobial treatment, prior to being treated with INPT for one week. INPT was implemented immediately after the initial blood sample was taken, consisting of 1-2 droppers, 2-3 times per day for no more than 5 days, of the INPT liquid solution, after which the treatment was discontinued.

One week after the discontinuation of the INPT treatment, the Phelix test was repeated to confirm all Borrelia were eliminated. All twelve patients who previously tested positive, were found to be negative on the second followup Phelix Borrelia-Phage Test.

Our study utilized the Phelix Borrelia-Phage test in that it is the premier, newest, most sensitive Borrelia lab test available. The Phelix test is statistically the most accurate test, undergoing quadruplicate real-time PCR tests for 3 different targets (B. burgdorferi sl, B. miyamotoi, Relapsing fever) for a total of 12 assessments. All positive-like samples are submitted to confirmatory sequencing to rule out false positive results. Before the Phage real-time PCRs, each sample is submitted to 2 rounds of QC to rule out false-negative results that would relate to the technical flaws: (i) to assess the quality of extracted DNA by performing low cycles actin PCR, and (ii) to assess the absence of PCR inhibitors by doing a real-time PCR for IAC (internal amplification control).

These results appear to demonstrate that this novel treatment, INPT:

  • Completely eradicates the Borrelia, Borrelia-persistor cells
  • Rapid eradication of all Borrelia, depending on the bacterial load, within 2-5 days
  • Apparent long-term elimination
  • Has no known adverse effects
  • Causes minimal Herxheimer reactions
  • Only affects the targeted type of bacteria, leaving friendly flora unaffected
  • Can be targeted to address any of the different strains of Borrelia sp.
  • Is designed to penetrate bacterial biofilms
  • Crosses the blood-brain-barrier
  • Being a complex frequency-based oral remedy it is completely non-toxic and non-allergenic
  • Does not require a healthy immune system

Eradication of Bacteria Never Corrects Damage to the Body

To date, many patients have undergone treatment with INPT, with over 60 Phelix Borrelia-Phage Tests being performed in total, the results of which are yet to be determined. Complete eradication and clinical cure, as mentioned in the article from Dr. Liegner, is a difficult issue to determine, since the eradication of the causative bacteria, while wonderful, does not repair the damage of having the infection for months, years, or even decades in some cases. However, the majority of patients have experienced more rapid and often more dramatic symptom-relief that would be expected with the disappearance of the offending bacteria, Borrelia. Symptom improvement has varied from each individual, with the most dramatic being a few individuals who were wheelchair bound due to their prolonged battle with the infection have been able to stand up from the wheelchair and in one case is able to walk.

Ongoing testing is underway to continue to document the long-term elimination of the Borrelia in these patients. No other treatments for Borrelia were used with the INPT, nor have any of the patients needed re-treatment for Borrelia in the months following their one week of INPT. To date, 100% of the people who had a negative on their second Phelix test also remained negative on a third Phelix test 45-60 days after the second test, without further treatment. Again, each of these blood samples were confirmed with quadruplicate qPCR testing for the Phelix Borrelia-Phage and another classic Borrelia qPCR test to confirm the results five times over.

The attraction of this work is obvious, however it is even more exciting when considering that if verified with continued INPT treatment and phage testing, the reality is that when there are no Borrelia bacteria or persistor cells left, a person will not be not in remission, as seen with conventional antibiotic treatment when symptoms abate for a period, but because a few bacteria remain in spite of prolonged antibiotic treatment, their illness may return. With none of the Borrelia left in the body, there is no remission from a small percentage of the bacteria persisting and reactivating, since all of the infection has been eliminated. Reinfection would require the person to acquire the infection by one of the many transmitting vectors, such as ticks.

With the laboratory confirmation of elimination of Borrelia, it appears that a person can now begin and end treatment of Borrelia within an unheard of two week period.

It must be reiterated that Lyme disease is much like having termites damaging the wood of your house. While killing all of the termites (Lyme microbes) is definitely a good thing, the killing of the bugs does nothing to repair the damage they caused in the wood of your house (your body). The first stiff wind will still stress or knock your house down. Instant resolution of all of a person’s symptoms is virtually impossible, even when all of the infection is gone, unless you were only recently infected and only minimal damage has been done to your body. The damage must be addressed in its entirety, in those people with chronic infection and many or severe symptoms.

To continue the house analogy, a hammer will not cut wood, although you cannot build and repair a house without one. In the same manner, an antibiotic or even INPT treatment that eliminates the bacteria is a tool that also just serves its purpose, but cannot repair damaged systems and tissues. One must have many healing tools in the toolbox, and the skill to use those tools, in order to restore optimum health once more.

INPT Does Not Cause a Major Herxheimer – Worsening of Symptoms

The delivery of the INPT treatment has been well-tolerated, even by people who are sensitive to almost all medicines, making it ideal for those with MCS, MCAS, and other hypersensitivity conditions.

The way phages kill a microbe causes much less “die-off” worsening of a person’s symptoms than antibiotics and other antimicrobial products. We now know from research that a “Herx” reaction is not actually from the bacterial guts (endotoxins) spilling into the body as the bacteria are killed as with antibiotics. A Herx reaction is due to the proinflammatory cytokines released by the body’s immune cells that engulfed the dying bacteria. With phage killing of the bacteria the bacteria explodes where it sits and only the debris is cleaned up by the immune cells. The debris does not cause much of a proinflammatory cytokine release and therefore the best treatment outcome is possible, faster and complete annihilation of the target microbe, with less worsening of the patient’s symptoms.

Ongoing Development of INPT at the Biologix Center

INPT was developed by Phagen Corp. and is being used at the Biologix Center for Optimum Health, as a part of an IRB study, to go beyond Borrelia and target any microbial issue, including all of the co-infections associated with Lyme disease, as well as Candida sp., mold, and parasite infections, however at this time the only lab test for detecting bacteria-specific phages is for Borrelia strains.

The future of INPT includes intravenous and injectable, in addition to the oral medication, through doctors only. It is not projected to sell directly to the public at this time.

If you would like to participate in our one to two week INPT programs please contact us at www.biologixcenter.com/get-treatment/. Financial assistance is available for those with chronic illness of any type, who desire treatment at Biologix Center and are struggling financially.

A more detailed report of these findings are presently being edited for publication in peer-reviewed article submission.

Bartonella Research Collaboration

The Biologix Center is collaborating with researchers who are working to develop phage lab tests for Bartonella and other types of microbes. The Phelix Bartonella-Phage Test is hoped to be offered before the end of 2020. If you have been diagnosed with Bartonella and would like to contribute a blood sample for the development of this new test, please let us know. Offer available only to patients of the Biologix Center who have been pre-qualified by our testing.

To learn more about Bacteriophages and INPT please click on the hyperlink.

*INPT is a patent-pending innovation developed by Phagen Corp, and is being researched at the Biologix Center for Optimum Health, in Franklin, Tennessee. A patient-funded, Retrospective Registry IRB is in place to publish peer-reviewed articles as this clinical work progresses. Approximately 98% of funds go to support the ongoing research.

There are no financial or academic conflicts to be reported between Biologix Center for Optimum Health and RED Laboratories.